Comparing the current results to its competitors, Mereo Biopharma Group Plc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.95 %, recorded in the same quarter.
Mereo Biopharma Group Plc, slower than the average decrease reported by the company's competitors of -55.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.9 %
January 8, 2024
Mereo BioPharma, a leading biopharmaceutical company with the chief aim to develop and commercialize innovative therapeutics, has recently provided an update on its formidable pipeline progress and corporate developments. Mereo is setting significant milestones with its strategic focus on rare diseases with the potential to transform the life of patients globally. The company has announced that the Phase 3 part of the Orbit Study and the Phase 3 Cosmic Study of setrusumab for the treatment of Osteogenesis Imperfecta (OI), conducted by its partner Ultragenyx, are expected to complete enrollment around the end of the first quarter and first half of 2024, respectively. This advancement signifies a crucial stage...
Publicly Traded Peers of Mereo Biopharma Group Plc
Astrazeneca Plc Share Performance
+1.13%
Over The Past 5 Days
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Sources:
Mereo Biopharma Group Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mereo Biopharma Group Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
